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Psychosocial Stress, Cortisol Levels,
and Maintenance of Vaginal Health
Emmanuel Amabebe and Dilly O. C. Anumba*
Academic Unit of Reproductive and Developmental Medicine, University of Sheffield, Sheffield, United Kingdom
Stress stimuli are ubiquitous and women do not enjoy any exemptions. The
physiologic “fight-or-flight” response may be deleterious to the female lower genital
tract microbiome if the stress stimuli persist for longer than necessary. Persistent
exposure to psychosocial stress and stimulation of the hypothalamic-pituitary-adrenal
(HPA) and sympathetic-adrenal-medullary (SAM) axes, and associated hormones are
risk factors for several infections including genitourinary tract infections. Though this
could be due to a dysregulated immune response, a cortisol-induced inhibition of
vaginal glycogen deposition may be involved especially in the instance of vaginal
infection. The estrogen-related increased vaginal glycogen and epithelial maturation
are required for the maintenance of a healthy vaginal ecosystem (eubiosis). The ability
of cortisol to disrupt this process as indicated in animal models is important in the
pathogenesis of vaginal dysbiosis and the subsequent development of infection and
inflammation. This phenomenon may be more crucial in pregnancy where a healthy
Lactobacillus-dominated vaginal microbiota is sacrosanct, and there is local production
of more corticotropin-releasing hormone (CRH) from the decidua, fetal membranes
and placenta. To highlight the relationship between the stress hormone cortisol and
the vaginal microbiomial architecture and function, the potential role of cortisol in the
maintenance of vaginal health is examined.
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INTRODUCTION
Stress is an organism’s attempt to adequately respond to either internal or external threats or
injuries. It refers to any physical or psychological challenge that threatens or has the potential of
threatening the equilibrium of an organism’s internal milieu (homeostasis) (1–3). Such challenges
could be life events, situations, emotive feelings, and interactions that adversely affect the
individual’s wellbeing or trigger perceived harmful responses. Psychosocial stress stimuli comprise
life experiences that include changes in personal life and relationships, occupation, housing, family
composition, and domestic violence necessitating adaptive survival behaviors/responses from the
affected individual (4, 5). Stress stimulates the hypothalamic-pituitary-adrenal (HPA) axis, which
eventually leads to elevated levels of cortisol. As a downstream effector of the stress-induced
neuroendocrine response, cortisol exerts global effects in the body to maintain homeostasis and
enhance the organism’s capacity to respond to and grapple with physical and emotional stresses
(6). For instance, it primes the organism for “fight or flight” by promoting energy metabolism
via glycogenolysis, gluconeogenesis, proteolysis and lipolysis, as well as regulates several immune
and inflammatory responses (7). Furthermore, it increases blood pressure, has diverse bone effects,
elicits both positive and negative effects on cell growth, and facilitates apoptosis in certain cell types,
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including certain neuronal cells (8). Normal immune function
may be impaired or dysregulated by exposure to chronic stress
through the HPA axis and the sympathetic-adrenal-medullary
(SAM) axis, resulting in the chronic production of glucocorticoid
hormones and catecholamines (9)
Cortisol is a steroid (glucocorticoid) hormone produced by
the zona fasciculata of the adrenal cortex within the adrenal
gland. It is released by the adrenal glands as part of the
fight-or-flight mechanism in response to stress or fear, but
has been described as public health’s foremost enemy (10).
Its functions include the modulation of increased blood sugar
through gluconeogenesis and induction of insulin resistance
(11, 12), metabolism of fat, protein, and carbohydrates, growth
and reproduction, immune suppression (13), sodium-potassium
transport (14, 15), cognition and memory (13, 16), and the
regulation of bone formation (17).
The release of cortisol is regulated by the HPA axis via
the secretion of corticotropin-releasing hormone (CRH) by
the paraventricular nucleus (PVN) of the hypothalamus, which
stimulates corticotrophs in the anterior pituitary to secrete
adrenocorticotropic hormone (ACTH, corticotropin), which
travels through the bloodstream to the adrenal cortex. ACTH
stimulates the synthesis of cortisol and other glucocorticoids.
Cortisol ultimately inhibits theHPAneuroendocrine response via
a negative feedback mechanism to restore a steady state (13, 18).
Cortisol has a circadian rhythm with lowest levels at midnight
and peak levels (∼399 nmol/l) in the morning (around 8:30) (19).
Hitherto, most studies have attributed the pathogenesis
of stress-related vaginal dysbiosis solely to impaired immune
function and loss of Lactobacillus species dominance (9, 20),
while others have merely enumerated the use of corticosteroids
as a factor associated with Bacterial vaginosis (BV). However,
the mechanisms by which cortisol, the classical stress hormone,
modulates the estrogen-induced deposition and accumulation
of glycogen in the vaginal epithelium and the implications for
maintenance of vaginal homeostasis has received little attention.
Due to the importance of the association between vaginal
glycogen, Lactobacillus species dominance and low pH for the
reproductive health of women, i.e., reducing the risk of sexually
transmitted infections (STIs), BV, and preterm labor (21), this
review examines the vaginal glycogen response induced by
estrogen and the potential repressive role of cortisol.
Literature Search
With the use of words and phrases including (but not limited
to) “stress and vaginal health,” “stress and bacterial vaginosis,”
“stress and vaginal infection,” “stress and immune function,”
“stress and vaginal Lactobacilli,” “stress, infection and preterm
Abbreviations: ACTH, adrenocorticotropic hormone; BV, bacterial vaginosis;
cAMP, cyclic adenosine monophosphate; CCL5, Chemokine (C-C motif)
ligand 5; CRH, corticotropin-releasing hormone; DES, diethylstilboestrol; HPA,
hypothalamic-pituitary-adrenal; IFNγ, interferon gamma; IL, interleukin; IL-
1RA, interleukin-1 receptor antagonist; NF-κB, nuclear factor kappa-light-
chain-enhancer of activated B cells; NGAL, neutrophil gelatinase-associated
lipocalin; PVN, paraventricular nucleus; SAM, sympathetic-adrenal-medullary;
SLPI, secretory leucocyte protease inhibitor; TLR, toll-like receptors; TNF-α,
tumor necrosis factor alpha.
birth,” “corticosteroids, cortisol and bacterial vaginosis,” “cortisol
and vaginal infection,” “cortisol and vaginal Lactobacilli,”
“cortisol and vaginal glycogen,” “estrogen, vaginal glycogen
and Lactobacillus dominance,” a comprehensive search was
conducted for scientific, peer-reviewed and published original
research articles involving both humans and animal models,
as well as review articles in PubMed/MEDLINE and Web of
Science databases between December 2017 and August 2018. In
order to comprehensively review relevant literature relating to
psychosocial stress, cortisol levels, and maintenance of vaginal
health, publication dates were not restricted. Articles not written
in English or including other hormones not directly involved in
the HPA or SAM stress axes and vaginal microbial composition
(e.g., insulin), were not included.
NORMAL VAGINAL MICROENVIRONMENT
The human vagina is not only a passage for sperm, menstruum,
and the baby but also a particularly versatile organ with a
protective epithelium and a rich diverse microbial landscape
(22). The vaginal microbiome comprises of a stratified squamous
non-keratinized epithelium overlaid by a mucin-rich mucus
layer and provides an attachment surface for the commensal and
most dominant lactic acid producing Lactobacillus species. The
most often identified species of Lactobacillus are L. crispatus,
L. jensenii, L. gasseri, and L. iners (23, 24). Other bacteria
endogenous to the normal vaginal microenvironment albeit
with low virulence capacity include Gardnerella, Prevotella,
Fusobacterium, Atopobium, Streptococcus, Staphylococcus,
Peptostreptococcus, Porphyromonas etc. These potentially
pathogenic bacteria are kept dormant by the acidic milieu
(pH 3.5–4.5) created by Lactobacilli amongst other protective
mechanisms including production of lactic acid (∼110mM)
(25, 26), hydrogen peroxide (H2O2), antimicrobial peptides
and by competitive exclusion i.e., physically preventing the
attachment of pathogens to vaginal epithelium (22, 27, 28). The
commensal and potentially harmful vaginal microorganisms,
their genes and products collectively form the vaginal microbiota
that dwell in a regulated mutualistic relationship with the host
vaginal epithelium to form the microbiome (29).
The vaginal microbiota in childhood until puberty is
dominated by anaerobes due to low glycogen content, a decrease
in Lactobacilli and other acid-producing microbes and a more
alkaline pH (30). This increases their susceptibility to genital
infections (e.g., vulvovaginitis) by a variety of aerobic and
anaerobic pathogens including S. pyrogens, N. gonorrhea, E. coli,
E. faecalis, C. vaginalis, Mycoplasmas, Diphtheroids, Bacteroides,
S. epidermidis, C. albicans etc. (31–35). Fortunately, due to
lack of exposure to sexual intercourse (coitus), the incidence
of genital tract infections is low in children except in cases
of child sexual abuse (36–38). At puberty, under the influence
of rising estrogen levels, the vaginal epithelium thickens and
stratifies, intracellular glycogen levels increase and undergo
cyclical changes, cervicovaginal secretions are produced, and
proliferation of lactic acid-producing lactobacilli commence (30,
39). The increasing production of lactic acid by Lactobacillus
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suggests there is a fermentable substrate present in the vagina.
Glycogen is identified as the suitable carbohydrate substrate as an
association between high acid secretion and presence of glycogen
in the vagina was demonstrated over 80 years ago (40). Vaginal
glycogen is degraded by host α-amylase into maltose, maltotriose
and α-dextrins, which are then converted to lactic acid by
Lactobacilli (21, 39, 41–43). Elevated estrogen and glycogen
levels promote increased thickness of the stratified squamous
epithelium and protective mucus layer of the vagina (44). Lactic
acid at physiological concentration (1% w/v, ∼110mM) (25, 26,
45) reduces the vaginal pH, which encourages the proliferation of
Lactobacilli and inhibits the growth of the anaerobes and viruses
capable of causing infection (26, 39, 45–49). It also exhibits
some immunomodulatory effects on cervicovaginal epithelial
cells and other cell types. It stimulates an anti-inflammatory state
through the increased production of IL-1 receptor antagonist
(IL-1RA) from cervicovaginal epithelial cells and inhibits the
activation of nuclear factor- κB (NF-κB) in peripheral blood
mononuclear cells and monocytes-macrophages (50, 51), which
promotes the transcription of pro-inflammatory target genes.
In addition, it inhibits the Toll-like receptor (TLR)-induced
production of inflammatory mediators from cervicovaginal
epithelial cells. Both D- and L-lactic acid exhibit these anti-
inflammatory effects that are potentiated by low pH <3.86
(22, 49, 52). The homeostatic vaginal environment created by
lactobacillus-dominant microbiota is temporarily altered during
menstruation when there is a decline in estrogen and glycogen
levels, and neutralization of the acidic pH promoting the
growth of pathogenic bacteria such as Gardnerella, Prevotella,
and Atopobium (53). After menstruation, the normal pH and
Lactobacillus dominance are re-established as estrogen levels
begin to rise again (54).
The vaginal microbiota in normal pregnancy is predominated
by Lactobacilli species and is more stable than that in
non-pregnant state (55, 56). This can be explained by
the higher level of estrogen during pregnancy resulting in
increased vaginal glycogen deposition, which enhances the
proliferation of lactobacilli-dominated vaginal microbiota. As
discussed later in this article, oestriol, which is one of three
major endogenous estrogens produced in significantly larger
amounts by the placenta during pregnancy (57), was as potent
as 17β-oestradiol (the most common form of estrogen in
non-pregnant premenopausal women) in stimulating vaginal
glycogen deposition (58).
Following menopause, Lactobacilli dominance decreases
secondary to diminished estrogen levels (59, 60) and cessation
or decline of glycogen production (61). Loss of Lactobacilli
increases vaginal pH to a more alkaline environment, providing
a conducive habitat for colonization by anaerobes (possibly of
fecal origin) and other pathogens (30, 62). For instance, post-
menopausal women showed lower free genital fluid glycogen
levels (41), and harbored more of G. vaginalis, Bacteroides,
Peptostreptococcus, Streptococcus, and Prevotella (63) compared
to premenopausal women who had higher free glycogen (41)
and preponderance of L. crispatus and L. iners (64). Topical or
systemic hormone replacement therapy and probiotics restore
vaginal Lactobacillus dominance and homeostasis with increased
acidity (65), and improves vaginal symptoms in post-menopausal
women (44). In some cases, there is a decrease in the prevalence
of anaerobic gram-negative rods and vaginal pHwhile the aerobic
isolates including Lactobacilli remain fairly constant (65).
Though progesterone alone and in combination with estrogen
greatly increases the glycogen concentration in the vaginal
epithelium in squirrel monkeys (66), it does not appear to have
the same effect in humans (58). For instance, progestin-only
contraceptive drugs such as Depomedroxyprogesterone acetate
(Depo-Provera) can produce a systemic hypoestrogenic state
associated with slight thinning of the glycogen vaginal epithelial
layer and reduced Lactobacillus colonization compromising
the vaginal barrier against infection (67, 68). In fact, a
significant negative correlation between free vaginal glycogen and
progesterone level was recently reported in genital fluid samples
of premenopausal women (42).
Also, the estrogenization and the subsequent production of
glycogen by the vaginal epithelium have been shown to promote
infection by Candida albicans (69). Glycogen was suggested to
be a suitable substrate for C. albicans. This was particularly
seen in post-menopausal women on systemic or vaginal estrogen
therapy, whereas in a more recent study with premenopausal
women, vulvovaginal candidiasis was observed in women with
low vaginal α-amylase activity (43). There is a need to investigate
the relationship between α-amylase activity and Lactobacillus




The effect of stress on the incidence of BV may be mediated
by stress-related dysregulation of immune function rather than
behavioral changes associated with stress (20). An optimal
immune response is required to prevent proliferation of BV-
associated anaerobes. A sub-optimal response perhaps secondary
to genetic polymorphism increases the risk of infection (70), and
may allow more ascending genital tract infection (71). Stress
enhances the progression of infection (including BV) and its
pathophysiologic consequences (72, 73).
Perceived psychosocial stress is significantly and
independently related to incidence and prevalence of BV in
pregnant (74) and non-pregnant women (20). Some stress
stimuli that can increase the risk of BV independent of individual
behaviors include challenging life conditions such low income,
poor housing, and dangerous neighborhood conditions, poor
nutrition and interpersonal conflicts (73, 75). These studies
assessed the level of stress exposure using the Cohen Perceived
Stress Scale (20, 74, 75). Chronic psychosocial stress is also an
established risk factor for preterm delivery independent of other
biomedical and behavioral risk factors (2). Stress regardless of
pregnancy status can range from acute and severe (e.g., trauma),
moderate (e.g., change in life events), and chronic (e.g., standing
for long hours as part of daily occupation). Nevertheless, during
pregnancy, both short- and long-term stress exposure can lead
to adverse pregnancy and delivery outcome (5, 76–78), though
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some studies with in vitro fertilization (IVF) patients argue
otherwise showing only minimal association between prenatal
stress and adverse pregnancy outcome (79).
Stress-induced cortisol binds to glucocorticoid receptors
expressed on a range of immune cells and alters NF-κB activities,
which regulates the activity of inflammatory mediators such
as cytokines (IL-1β, IL-6, TNF-α, IFNγ) and chemokines (IL-
8, CCL5). Glucocorticoids also facilitates immunosuppression
by inhibiting proliferation, migration and cytotoxicity of
lymphocytes and leukocytes, and secretion of IL-2 and IFN-
γ (73). On the other hand, stress-induced epinephrine and
norepinephrine bind to adrenergic receptors, activate cAMP and
stimulate the transcription of genes encoding for a variety of
inflammatory mediators (9, 80). Higher stress scores correlate
with higher levels of IL-6 and TNF-α; and with low levels
of the anti-inflammatory cytokine IL-10 (5). Furthermore,
stress hormones increase vulnerability to infections that are
primarily prevented by innate and adaptive immune responses
by differentially regulatingmonocyte, macrophage, Th1/Th2 cells
and cytokine expression patterns (81–84). These cortisol and
catecholamines-mediated changes in gene expression dysregulate
immune function (9). However, with previous observation
of stress-related alterations in production of inflammatory
mediators that are not associated with serum cortisol levels (85),
the impact of stress on immune function may not be limited to
cortisol-mediated effects alone (20).
A stress-induced vaginal dysbiosis with disrupted vaginal
mucosal and immune response-related proteins (e.g.,
lactoferrin), reduction in neutrophil bactericidal potency
and reduced abundance of commensal Lactobacillus have been
demonstrated in a mouse model (86). Reduced Lactobacillus was
associated with overgrowth of other microbes (86), most likely
anaerobic and facultative bacteria. Exposure to stress produces
a significant decrease in the abundance of vaginal Lactobacillus
species and can amplify the severity and consequences of vaginal
infection (27). This occurs through the release of CRH, which
stimulates sympathetic nerve terminals and the SAM axis to
release norepinephrine. Norepinephrine can enter the vagina
from the bloodstream and is locally secreted by vaginal epithelial
cells to which it binds (80). Though the vaginal epithelial cells
in this in vitro experiment were exposed to a high range of
norepinephrine concentrations (1-10µM), this may not differ
significantly from the in vivo environment. This is supported
by evidence of abundant supply of norepinephrine from nerve
terminals innervating the cervicovaginal mucosa in humans and
animals (87–91) and vaginal epithelial cells could potentially
interact with norepinephrine in the circulation as well (80). In
addition, local production of norepinephrine by epithelial cells
in other sites such as the cornea has been demonstrated (92). The
combined effect of a depleted vaginal Lactobacillus dominance,
which leads to decreased lactic acid and H2O2 production and
increased alkalinity and proliferation of pathogenic bacteria;
and increased norepinephrine secretion result in a heightened
pro-inflammatory response with increased production of
cytokines and chemokines [(27); Figure 1]. In essence, high
norepinephrine levels induced by severe stress, potentiates the
pro-inflammatory response of vaginal epithelial cells possibly in
an autocrine fashion in the presence of diminished Lactobacilli
and low pH (80).
It also noteworthy that the incidence and prevalence of BV
is influenced by other factors including frequent unprotected
sexual activity with new or multiple partners (93–96), smoking,
alcohol and drug use (73, 96–99), contraceptive practice (97, 98,
100), vaginal douching (95, 97, 101), menstruation (102, 103),
pregnancy (96, 104), low educational and socioeconomic status,
and black race (73, 95–98, 100, 105). Nevertheless, after adjusting
for all of these associated factors that usually account for only
minimal proportion of the variation in BV, the relationship
between psychosocial stress and aberrant vaginal microbiota has
been shown to be maintained in several studies (20, 74). The
pathophysiology, risk factors and consequences of BV and other
female genital tract infections have been reviewed extensively
(22, 106), and more investigation is recommended due to the
enigmatic nature of these conditions especially BV.
CORTISOL INHIBITS VAGINAL GLYCOGEN
DEPOSITION
The vaginal glycogen deposition action of estrogen was
demonstrated over 50 years ago. Wrenn and colleagues in
an attempt to determine the estrogen content of biological
fluids, observed a rapid increase in vaginal glycogen content
after locally administering estrogen extracted from human and
cow urine and blood samples to adolescent, ovariectomized
rats (58). This was termed the “vaginal glycogen assay for
estrogen.” Furthermore, they investigated the specificity of
the assay by comparing the effect of 17β-oestradiol with
progesterone, cortisol, deoxycorticosterone, testosterone and
diethylstilboestrol (DES, synthetic non-steroidal estrogen), both
individually and in combination with 17β-oestradiol. Of all these
hormonal substances, which are equally applied intravaginally,
only DES stimulated a vaginal glycogen response singly, which
was significantly enhanced in combination with 17β-oestradiol.
Interestingly, the hormones associated with stress i.e., cortisol (30
µg/0.01ml) and deoxycorticosterone (40 µg/0.01ml) exhibited
moderate inhibition of the glycogen response when administered
in combination with 17β-oestradiol, while progesterone and
testosterone were ineffective in this regard. In addition, the
vaginal glycogen action of the other two naturally occurring
forms of estrogen was tested. It was observed that oestrone which
is usually found in post-menopausal women was only about 10%
as active as 17β-oestradiol, whereas oestriol (common during
pregnancy) was as potent as 17β-oestradiol (58). This gives
more credence to the more stable Lactobacilli dominated vaginal
microbiota rich in glycogen and lactic acid content observed
in healthy pregnant women. However, because this experiments
were conducted in rats with relatively high concentrations of
cortisol (8.3 × 106 nmol/l) compared to circulating cortisol
levels under maximum stress such as major surgery (726 and
1297 nmol/l) (107, 108) or intravenous administration of 50mg
hydrocortisone (2450 nmol/l) (109) in humans, more empirical
evidence from human experiments is required. Perhaps the local
(cervicovaginal) concentrations of cortisol as demonstrated by
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FIGURE 1 | Stress-related reduction in vaginal Lactobacillus dominance (dysbiosis) and dysregulated immune response. Exposure to psychosocial stress induces the
release of cortisol and norepinephrine via the hypothalamic-pituitary-adrenal and SAM axes respectively. Cortisol inhibits the estrogen-related vaginal epithelial
maturation and glycogen accumulation. Levels of vaginal free glycogen and Lactobacilli are reduced leading to decreased lactic acid and hydrogen peroxide (H2O2)
synthesis and pH. Consequently, a dysbiotic environment conducive for the proliferation of bacterial vaginosis-associated anaerobic bacteria such as Gardnerella,
Prevotella, Mobiluncus, Atopobium, Megasphera, and sexually transmitted infections such Neisseria gonorrhea, Chlamydia trachomatis, human immunodeficiency
virus is created. Cortisol also affects immune response by altering the nuclear factor-κB (NF-κB) signal transduction pathway, which regulates inflammatory gene
expression. These effects are exacerbated by the concurrent release of norepinephrine, which binds to vaginal epithelial cells and potentiates the pro-inflammatory
response via a reduction in the release of antimicrobial proteins including mucins, immunoglobulins (secretory Ig A and IgG), β-defensins, secretory leucocyte protease
inhibitor (SLPI), and neutrophil gelatinase-associated lipocalin (NGAL). The overall effect is a dysbiotic vaginal ecosystem with a sub-optimal immune response, which
encourages upper genital tract infection with deleterious gynecological and obstetric sequelae.
Wrenn et al. (58) is more crucial in the glycogen response than
the influence of circulating cortisol as reported in humans. More
so, it could be that such repressive effect on vaginal glycogen
deposition in humans could only be attained via a combined
local action of cortisol and norepinephrine that mediate the
physiologic stress response. This is yet to be demonstrated in
human specimens.
The above evidence could be one mechanism through
which frequent use of corticosteroids alters the equilibrium
of the vaginal microbiome apart from dysregulated immune
response. Cortisol repressed the estrogen-related maturation
of vaginal epithelial cells and glycogen accumulation. If
this happens in humans, the breakdown of glycogen to
smaller polymers by α-amylase is reduced leading to low
lactic acid production and ultimately loss of Lactobacillus
dominance. This recipe creates a conducive, less acidic ecosystem
for infection by strict and facultative anaerobic bacteria,
viruses, fungi, and protozoa (27). Because the maturation
of the vaginal epithelium is impaired, there is inadequate
secretion of mucins and other antimicrobial proteins such
as secretory leukocyte protease inhibitor (SLPI), neutrophil
gelatinase-associated lipocalin (NGAL), and β-defensins. In
addition, cortisol also alters NF-κB activity and dysregulates the
expression of pro-inflammatory cytokines and chemokines (9).
The combined effect is a dysregulated/ineffective inflammatory
response against the pathogens, and an uncontrolled and possibly
ascending genital tract infection, which can be deleterious
especially during pregnancy.
Since stress is almost inevitable, these actions of cortisol have a
propensity to disrupt the equilibrium of the vaginal microbiome
and its capacity to combat infectious agents. Excessive exposure
to psychosocial stress is independently associated with increased
prevalence of BV (20, 73–75), which is the most common
vaginal condition in women of reproductive age. BV is a
quintessential dysbiotic condition characterized by overgrowth of
anaerobic gram-negative and gram-variable bacteria secondary
to a decrease in the protective Lactobacillus species. During
pregnancy, BV has been linked to stress and it increases the
risk of preterm labor by ∼3-fold (110). Infections such as
BV can lead to ascending intrauterine infection that stimulates
immune responses with release of inflammatory mediators,
uterotonins (Prostaglandins, PGs) and extracellular matrix
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degrading enzymes (e.g., matrix metalloproteinases, MMPs).
These inflammatory cytokines, chemokines, PGs, and MMPs
stimulate the pathway to premature rupture of membranes and
preterm birth i.e., uterine contraction, cervical ripening, and
membrane activation, via a positive feedback loop (22, 28, 106,
110).
While studies on stress and vaginal dysbiosis are often
done without measurement of cortisol levels (20, 74, 75,
111); and others did not find a clear pattern of association
between perceived stress (resulting from change in relationships,
sickness/injury, finances, work pressure or routines, unpleasant
events, and relationship pressure) (111) or stress hormones and
BV (112); the disruptive role of cortisol on the vaginal microbiota
and immunity has been highlighted by the experiments ofWrenn
et al. (58), albeit in animal models studied with significantly
higher cortisol concentrations. Also, the correlation of cortisol
levels with the prevalence of BV and other genitourinary
tract infections in humans has been reported (113). In fact,
a significant increase in cortisol across the 2nd and 3rd
trimesters was observed in patients with BV, an association
hypothesized to be restricted to a local response to cortisol
(113). Elevated cortisol levels could correlate with reduced
vaginal glycogen content, loss of Lactobacillus dominance,
decreased acidity, dysbiosis, and increase production of pro-
inflammatory mediators. More so, it is plausible that increased
norepinephrine activity, which in concurrence with cortisol
is involved in the “fight-or-flight” response and has been
shown to potentiate the pro-inflammatory response of vaginal
epithelial cells, amplifies these actions of cortisol (Figure 1).
Furthermore, since vaginal glycogen deposition is not required
for immediate survival during exposure to stressful stimuli and
subsequent “fight-or-flight” response, cortisol’s action appears
to be an adaptive mechanism to preserve energy sources for
organs such as the brain, cardiac and skeletal muscles albeit
with unpleasant reproductive consequences when prolonged. A
more comprehensive investigation to elucidate the mechanisms
of cortisol’s action on the human vaginal microflora and the
consequent gynecological and obstetric health implications is
required.
STRESS-INDUCED ALTERED MATERNAL
VAGINAL AND OFFSPRING GUT
MICROBIOTA
Exposure to chronic psychosocial stress during pregnancy may
amplify the physiologic pregnancy-induced immunosuppression
(114). This can increase the risk of dysbiosis, recurrent
genitourinary infection and eventual loss of the beneficial
lactobacillus-dominated vaginal microbiota as seen in BV and
candidiasis (115, 116). Since the initial neonatal gut microbial
colonization is dependent on vertical transmission from the
maternal vaginal microbiota during parturition, acquisition of
a dysbiotic lactobacillus-depleted microbiota predisposes the
infant to altered gastrointestinal tract maturation, impaired
extraction of energy and macromolecules essential for normal
growth and development, and dysfunctional immune system.
This eventually increases the infant’s risk of disturbed energy
metabolism, obesity, insulin resistance, and diabetes mellitus.
Other conditions include diarrheal illness, food allergy,
atopic diseases, and inflammatory bowel disease, and irritable
bowel syndrome (117, 118). Also, the risk of long-term
neurodevelopmental disorders due to reprogramming of the
developing brain has been reported (86, 114, 119). These
findings are supported by human studies and experiments
with animal models. For instance, infants of mothers with
high prenatal stress (reported and due to high cortisol
levels) had significantly lower relative abundance of lactic
acid-producing bacteria including Lactobacillus, Lactoccus,
Aerococcus, and Bifidobacteria; and higher relative abundance
of Proteobacteria including the pathogenic E. coli, Serratia,
and Enterobacter. This dysbiotic microbiota is potentially
associated with an increased level of lipopolysaccharide
(LPS)-induced inflammation and more maternally-reported
infant gastrointestinal symptoms and allergic reactions
(118).
Furthermore, female rhesus monkeys exposed to moderate
stress (acoustic startle) for 6 weeks in later gestation showed
activated HPA axis and increased cortisol levels (above those
found in normal pregnancy), that was sufficient to cause altered
intestinal microbiota characterized by decreased protective
Lactobacilli and Bifidobacteria in their offsprings (120). Reduced
concentrations of Lactobacilli and total and Gram-negative
aerobes and facultative anaerobes have also been observed
in the small intestine of pups whose mothers were injected
with cortisone before birth (121, 122). These animal studies
have provided ample evidence that the relationship between
prenatal psychosocial stress and offspring programming is
mediated, at least in part, by elevated cortisol levels (119). The
pathophysiology of the effect of prenatal stress on maternal
gut/vaginal and fetal gut microbial composition, and the
development of insulin resistance, increased adiposity and
metabolic syndrome later in life in humans is beyond the scope
of this review but requires further investigation.
PREVENTIVE AND TREATMENT
STRATEGIES FOR STRESS-INDUCED
VAGINAL INFECTION AND INFLAMMATION
Optimal preventive/treatment approach to counteract the
effect of stress on vthe aginal microenvironment should aim
to alleviate or eliminate the stress stimuli and the associated
infectious and inflammation agent(s). Though stress is almost
inevitable, some life modifications can help an individual
cope with stressors better. These adaptive measures include
regular physical exercise, healthy eating, having adequate
sleep and avoiding unhealthy habits like smoking, alcohol,
and drug abuse. In addition to eliminating stressors and
lifestyle modifications, appropriately administered antibiotics or
antifungal agents can eliminate bacterial and fungal infections
while inflammation can be targeted pharmacologically using
anti-inflammatory agents. This is an important therapeutic
goal because inflammation can persist even after the stress
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stimuli or infectious agents have been eliminated (22). Antibiotic
treatment may also alter the vaginal bacterial composition
with potential colonization by opportunistic pathogenic
agents (123).
Another potential approach to restoring and/or maintaining
vaginal homeostasis that avoids the adverse effect of antibiotics
on beneficial microbiota (124) is the use of probiotics e.g.,
Lactobacillus species (L. crispatus), and prebiotics such as
D-lactic acid, glycogen, oligosaccharide etc. that stimulate
probiotic bacterial growth (22, 124–131). Recently, in a study
including 6 women, 5 of whom were pregnant, vaginal, and
oral lactoferrin administration improved vaginal microbiota
Lactobacillus dominance and prevented refractory BV, cervical
inflammation, and preterm delivery (132). This has previously
been attempted with similar results by the same group (133)
and others (134); and gives credence to the observed altered
vaginal microbiota (with decreased Lactobacilli and lactoferrin
levels) when mice were exposed to mild prenatal stress (86).
A combination of probiotics and prebiotics could provide
clinically useful adjunct to pharmacological and other strategies
for treating/preventing vaginal infections and women’s health in
general (129, 131).
Some anti-inflammatory agents that can block LPS-driven
production of cytokines (e.g., TNF-α, IL-6 and IL-1β) as
observed in stress-induced vaginal colonization by anaerobic
bacteria include phosphodiesterase (PDE) inhibitors, MAP
kinase inhibitors, TNF biologics and NF-κB inhibitors (135).
Some of these agents have also been applied in the prevention
of LPS-stimulated preterm birth and fetal death (136, 137).
With further exploration of the clinical utility, safety and
toxicity of these anti-inflammatory agents, various stages of
the stress/infection-associated inflammatory process can be
targeted. However, because NF-κB is the “master regulator”
of inflammatory gene expression, there is the crucial concern
that inhibiting the activation of NF-κB and/or other pro-
inflammatory mediators could prevent optimal activation of
host innate and adaptive immune responses and increase the
risk of infection. This could be deleterious particularly in an
immunocompromised state such as pregnancy (135, 138).
MAIN FINDINGS AND FUTURE DIRECTION
The potential action of the stress hormone cortisol in the
maintenance of vaginal health has been highlighted. Stress
stimuli are ubiquitous and women do not enjoy any exemptions.
The physiologic “fight-or-flight” response may be deleterious to
their lower genital tract microbiome if the stress stimuli persist
for longer than necessary. Persistent exposure to psychosocial
stress and stimulation of the HPA and SAM axes, with a
corresponding increase in cortisol and norepinephrine levels are
associated with dysbiosis and increased susceptibility to several
infections including genitourinary tract infections. Though this
could be solely due to a dysregulated immune response, a
cortisol-induced inhibition of vaginal glycogen deposition may
be involved especially in the instance of vaginal infection.
The estrogen-related increased vaginal glycogen deposition and
epithelial maturation are requirements for the maintenance of
vaginal eubiosis. The ability of cortisol to disrupt this process
as shown in animal models is important in the pathogenesis
of vaginal dysbiosis and subsequent development of infection
and inflammation. If proven in humans, this phenomenon may
be more crucial in pregnancy where a healthy Lactobacillus-
dominated vaginal microbiome is sacrosanct, and there is local
production of more CRH from gestational tissues including
the decidua, fetal membranes (chorioamnion), and placenta.
Because the current evidence of the repressive role of cortisol
on vaginal glycogen deposition involve experiments in animals
with high concentrations of cortisol compared to that observed
during severe stress in humans, further work especially in
humans is needed to elucidate the pathophysiologic association
between cortisol levels and vaginal microbiomial architecture and
function.
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